Research report: Real-world treatment patterns of galcanezumab versus traditional oral migraine preventives: 12-month results from the TRIUMPH study
A 12-month real-world study found galcanezumab patients discontinued preventive treatment less often and reported larger reductions in migraine headache days ...
